Company
HKEX:2629
Develops and sells blood-based microRNA diagnostic tests for early cancer detection. Its lead product, GASTROClear, is a 12-biomarker blood panel for gastric cancer screening; it also markets LUNGClear for lung cancer and Fortitude infectious-disease assays. The longevity relevance is early detection rather than any ageing-biology intervention: catching cancer at a screenable, asymptomatic stage in high-risk adults. Qualifies for the variis universe on the headquarters limb (Singapore), not the exchange limb, as it is listed on HKEX rather than SGX or ASX.
Thesis
Market data
| Metric | Detail |
|---|---|
| Exchange | HKEX |
| Ticker | HKEX:2629 |
| Secondary listing | None |
| Market cap | HK$3.66bn (approx US$470m) as at 31 March 2026 per stockanalysis.com, down from a HK$8.29bn debut valuation on 23 May 2025; no verified mid-2026 quote retrieved |
| Status | Listed and trading |
Get in touch
Offering
No commercial services are recorded for this company yet.
Recent inflection
9 October 2025: China's NMPA granted GASTROClear Class III IVD registration, making it the first non-invasive blood test approved for gastric cancer screening in China, cleared for high-risk adults aged 45 to 74 on the basis of a 9,472-subject prospective trial across seven Chinese academic centres (Mirxes media release).
Keep reading
Sources
Every entity profile on variis is sourced. Not investment advice.